Amedisys (NASDAQ:AMED – Get Free Report) is projected to announce its Q1 2025 earnings results before the market opens on Wednesday, April 23rd. Analysts expect Amedisys to post earnings of $1.13 per share and revenue of $597.43 million for the quarter.
Amedisys (NASDAQ:AMED – Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 EPS for the quarter, missing the consensus estimate of $1.05 by ($0.09). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The business had revenue of $598.05 million during the quarter, compared to analysts’ expectations of $602.38 million. On average, analysts expect Amedisys to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Amedisys Stock Performance
Shares of AMED stock opened at $91.83 on Tuesday. Amedisys has a one year low of $82.15 and a one year high of $98.95. The company has a 50 day moving average price of $92.13 and a 200 day moving average price of $91.83. The firm has a market capitalization of $3.01 billion, a price-to-earnings ratio of 36.44, a price-to-earnings-growth ratio of 1.78 and a beta of 0.89. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19.
Wall Street Analyst Weigh In
Check Out Our Latest Research Report on AMED
About Amedisys
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Featured Articles
- Five stocks we like better than Amedisys
- How to Evaluate a Stock Before Buying
- AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer Stock
- Dividend Capture Strategy: What You Need to Know
- Why Call Option Traders Are Targeting This Dividend ETF Now
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Is Alphabet Misunderstood? Here’s Why the Bulls Are Buying
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.